We report on a three-drug myeloablative regimen designed to consolidate remission and to prevent central nervous system (CNS) relapse of high-risk neuroblastoma (NB). Sixty-six NB patients received topotecan 2 mg/m 2 / day, Â 4 days; thiotepa 300 mg/m 2 /day, Â 3 days; and carboplatin B500 mg/m 2 /day, Â 3 days. Post-SCT treatments included radiotherapy, immunotherapy, 13-cisretinoic acid, 7oral etoposide. Significant nonhematologic toxicities were mucositis and skin-related in all patients, convulsions in three patients, and cardiac failure and venocclusive disease of liver in one patient each. Grade 2 hepatotoxicity led to truncating cytoreduction in two patients; both later relapsed in brain. Among 46 patients transplanted in first complete/very good partial remission (CR/VGPR), event-free survival is 54% (s.e.78%) at 36 months post-SCT; notable events were three non-NB-related deaths (adenovirus on day þ 9, bowel necrosis at 5 months, multiorgan failure at seven months) and four relapses in brain. Of 12 patients transplanted with evidence of NB, two became long-term event-free survivors and two relapsed in the brain. Of eight patients transplanted in second or greater CR/VGPR, one became a long-term event-free survivor and seven relapsed though not in the CNS. This regimen has manageable toxicity but does not prevent CNS relapse.
Introduction
Isolated relapses in the central nervous system (CNS) in patients with neuroblastoma (NB) whose sole systemic treatments were conventional chemotherapy and immunotherapy, 1 plus the 1999 report from Matthay et al. demonstrating improved outcome with myeloablative therapy, prompted us to devise a myeloablative regimen aimed at consolidating remission and preventing CNS relapse. Among the alkylating agents commonly used in anti-NB myeloablative regimens, we chose thiotepa because it has better CNS penetration than melphalan, is less toxic than busulfan, and, unlike cyclophosphamide, is not part of induction. We included carboplatin because of its excellent anti-NB activity and its relatively modest extramedullary toxicity even at very high doses. We considered etoposide, which is often in myeloablative regimens for synergistic antitumor effects, including in patients with brain tumors. However, NB transplant candidates have often already been treated with etoposide because this topoisomerase-II inhibitor is a common component of induction regimens. Furthermore, major toxicities of high-dose etoposidemucositis, hepatotoxicity, leukemogenicity -overlap with those of stem cell toxic alkylators. As an alternative, we chose topotecan because this topoisomerase-I inhibitor may be less affected by the most common multidrug resistance mechanisms, 3, 4 can potentiate antitumor effects of alkylating agents, 5 has good CNS penetration, 6 is active against NB, [7] [8] [9] [10] and causes little extramedullary toxicity. [7] [8] [9] [10] [11] [12] We now present our experience in NB patients treated with a myeloablative regimen that includes topotecan. We previously reported preliminary results with the same regimen, used against a variety of solid tumors. 13 Only one other report has appeared on a topotecan-containing myeloablative regimen for NB. 14 
Patients and methods
The subjects of this report are 66 Memorial SloanKettering Cancer Center (MSKCC) patients with high-risk NB including 46 patients in first complete remission (CR) or very good partial remission (VGPR), 12 patients with resistant disease, and eight patients in second or greater CR/VGPR. (Nine patients were included in the report on preliminary results with this regimen. 13 ) Eligibility requirements included adequate function of kidneys (creatinine clearance X60 ml/min/1.73 m 2 ), heart, and liver (p1.5 Â normal levels of serum transaminases and bilirubin), and informed written consent in accordance with hospital rules.
Treatment was over 6 days: topotecan 2 mg/m 2 by 30-min intravenous (i.v.) infusion on days À8, À7, À6, À5, À4 (total, 10 mg/m 2 ); thiotepa 300 mg/m 2 by 3-h i.v. infusion on days À8, À7, À6 (total, 900 mg/m 2 ); and carboplatin by 4-h i.v. infusion at B500 mg/m 2 /day on days À5, À4, À3 (total, B1500 mg/m 2 ). The exact daily dose of carboplatin was derived from the pediatric Calvert formula, 15 with a targeted area under the curve of 7 mg/mln min; hence, the daily dose was 7 mg/ml n min Â (raw creatinine clearance þ (body surface area in square meters Â 15)). However, the daily carboplatin dosage could not exceed 700 mg/m 2 . Stem cell transplantation (SCT) was on day 0 with autologous bone marrow (BM) or peripheral blood stem cells (PBSCs). Granulocyte colony-stimulating factor (G-CSF) 5 mg/kg i.v. twice daily was started on day þ 1 and total parenteral nutrition was started on day þ 2. Prophylaxis against Pneumocystis carinii was stopped on day À3, and prophylactic use of acyclovir was started on day À2 (i.e., after completion of all chemotherapy).
Subcutaneous injections of G-CSF (10-15 mg/kg per day for 2-7 days) preceded BM harvesting and PBSC collections. BM and PBSCs were not treated ('purged') ex vivo.
Post-SCT treatments included: 21 Gy local radiotherapy to the primary site and to previous sites of bulky metastatic deposits; 16 immunotherapy with the anti-G D2 3F8 monoclonal antibody alone 17 or with granulocyte-macrophage colony stimulating factor (GM-CSF);
18 and 13-cis-retinoic acid.
2 Some patients also received up to four cycles of oral etoposide. 19 Disease status was assessed by computed tomography (CT) or magnetic resonance imaging (MRI) of the primary site and head/orbits, 99m Tc-bone scan, 131 I-or 123 Imetaiodobenzylguanidine (MIBG) scan, histologic studies of BM biopsies and aspirates from bilateral iliac crests, and urine catecholamine measurements. Testing was repeated at 6-8 weeks post-SCT (before initiation of further therapy) and then every 3 months.
The International Neuroblastoma Response Criteria 20 were used: CR, no evidence of disease; VGPR, volume of primary mass reduced by 90-99%, no evidence of distant disease (including normal MIBG) except for skeletal residua, catecholamines normal; partial response (PR), 450% decrease in measurable disease and p1 positive BM site; mixed response (MR), 450% decrease of any lesion with o50% decrease in any other; no response (NR), o50% decrease but o25% increase in any lesion; and progressive disease (PD), new lesion or 425% increase in an existing lesion. Toxicity was graded using the National Cancer Institute Common Toxicity Criteria.
Kaplan-Meier plots were used to determine event-free survival from date of stem-cell rescue (day 0).
Results

Toxicity
All patients had grade 4 oropharyngeal mucositis, grade 3-4 skin toxicity with erythema and superficial peeling, and some degree of hearing loss. Other grade 3 or 4 toxicities were: death from adenovirus on day þ 9 in a patient who was one of three who had a generalized convulsion; venoocclusive disease (VOD) of the liver in a patient who was one of two who developed grade 3-4 hypertension; and congestive heart failure in one patient (cumulative doxorubicin 550 mg/m 2 ). Five patients had transient grade 3 elevations in liver function tests. Grade 2 increases in serum transaminases led to aborting cytoreduction as follows: one patient received no carboplatin and only four doses of topotecan, and one patient received only the first four days of the regimen. Therapy was altered in one other patient: the third dose of thiotepa was withheld due to a convulsion.
Two lethal problems may have been transplant-related: bowel necrosis on day þ 59 (44 days after discharge) with death three months later, and idiopathic multiorgan failure at 7 months post-SCT in the patient mentioned above with VOD (which had long since resolved).
Eight patients had blood-borne bacterial infections and one patient each had cytomegalovirus (antigenemia), respiratory syncytial virus, adenovirus (generalized and lethal -see above), and Herpes simplex type 6 variant B (DNA detected in BM during an evaluation for slow engraftment).
The median time to an absolute neutrophil count 4500/ ml was 10 days (range, 8-23 days) after PBSC infusion and 17 days (range, 11-40 days) in the 11 patients who received BM. Platelets were transfused every 1-3 days through median day 17 (range, 10-44 days) post-PBSC infusion and through median day 29 (range, 14-to-4100 days) post-BM infusion. Two patients received second infusions of BM on day 21 because of slow engraftment.
Patients transplanted in first CR/VGPR: characteristics and outcome
At the time of SCT, the 46 patients (25 males, 21 females) in first CR/VGPR were 1.1-23.7 years old (median, 3.5). Three patients had MYCN-amplified stage 3, three were o1 year old at diagnosis of MYCN-amplified stage 4, two were 1.1 years old at diagnosis of diploid but MYCNnonamplified stage 4, and 38 patients were 41.5 years old when diagnosed with stage 4. Induction in all but two patients included three or four cycles of high-dose cyclophosphamide-doxorubicin-vincristine and one or two cycles of high-dose cisplatin-etoposide, as in the N7 protocol. 21 Three patients with persistent NB in BM achieved CR only after treatment with 3F8/GM-CSF.
Event-free survival at 36 months is 54% (s.e.78%) (Figure 1) . Twenty-five patients remain event-free survivors 15 þ -63 þ months post-SCT (median, 41 þ ), including all three MYCN-amplified stage 3 patients, both patients aged 1.1 years at diagnosis, and two of the three patients who had required 3F8/GM-CSF to achieve pretransplant CR. Three patients died of toxic events nine days, 5 months, and 7 months post-SCT (see Toxicity above). The other 18 events were relapses; these occurred 2-48 months post-SCT (median, 11.5 m). The most common kind of relapse was in bone alone (n ¼ 8), all detected by routine monitoring studies. Relapse in BM occurred in only four patients, including one whose very early relapse (2 months post-SCT) also involved multiple bones and one whose very late relapse (48 months post-SCT) also involved the orbit. Two relapses were in soft tissue only. Table 1 summarizes CNS relapses. Three patients had isolated relapses in the brain found 10.5-14 months post-SCT, with one detected during routine follow-up studies and two marked by headaches. A fourth patient had an asymptomatic isolated relapse in the dura found 12 months post-SCT; it resolved with radiotherapy and chemotherapy but headache heralded relapse in the brain 19 months later. This patient's myeloablative therapy was incomplete, with no carboplatin and only four doses of topotecan (see Toxicity above).
Patients transplanted with resistant disease: characteristics and outcome At the time of SCT, the 12 patients (six males, six females) with resistant NB were 1.4-8.7 years old (median, 4.7). One patient had MYCN-amplified stage 3 and 11 had stage 4. Induction was varied but included two or more cycles of high-dose cyclophosphamide-based regimens and at least one cycle of high-dose cisplatin-etoposide. Pretransplant sites of disease were BM alone (n ¼ 5), a single focus of MIBG uptake in bone (n ¼ 4), soft tissue alone (n ¼ 2), and brain (n ¼ 1). Seven patients had primary refractory NB, four had secondary refractory NB, and one had PD. This last patient's pretransplant CT showed three new 4-7 mm foci in brain (not seen by MRI or MIBG scan). She received only four days of the myeloablative regimen (see Toxicity above); CT at 1 month post-SCT showed CR. However, she developed headaches 3.5 months post-SCT and had relapsed in the brain and BM (Table 1) . Headache was also the presenting symptom in another patient in this group who had an isolated CNS (brain) relapse, found 13 months post-SCT (Table 1) .
A total of 10 patients had PD 2-17 months post-SCT (median, 5). Two patients remain event-free survivors: one had primary refractory BM disease, was in CR immediately post-SCT, and is 48 þ months post-SCT, and one had secondary refractory NB, underwent resection post-SCT of a mandibular lesion, and is 50 þ months post-SCT.
Patients transplanted in second CR/VGPR: characteristics and outcome
At the time of SCT, the eight patients (six males, two females) in second (n ¼ 7) or greater (n ¼ 1) CR/VGPR were 4.0-17.0 years old (median 7.9). Seven had stage 4 with BM involvement and one had stage 4 with distant nodal but no BM involvement ('stage 4-N') . Two of the eight had previously received myeloablative chemotherapy. Treatment for relapse was variable, including surgery alone, 3-6 cycles of chemotherapy using high-dose cyclophosphamide-based regimens and high-dose cisplatin-etoposide, 131 I-MIBG therapy, and 3F8/GM-CSF. The patient with stage 4-N (MYCN-amplified) remains in second CR 41 þ months post-SCT. The other seven patients relapsed 4-23 months post-SCT (median, 14); no relapse was in the CNS.
Discussion
In high-risk NB patients, reasons for treatment intensification using topotecan, thiotepa, and carboplatin included the steep dose-response antitumor activity of alkylating agents, 24 evidence of noncross-resistance among alkylators, 25 and enhancement of alkylator cytotoxicity by topotecan. 26 Since all three agents are active against NB, 10, 27, 28 and enter the CNS, we postulated that their use together in high doses might help overcome two major problems -viz., minimal residual disease and CNS relapse. This three-drug regimen may have contributed to the longterm event-free survival of some patients, but one patient (and possibly two others) died of transplant-related toxicity and CNS relapse remained an issue.
We used all three agents at dosages identified in phase I-II studies as safe and effective: thiotepa achieved significantly better results at X900 mg/m 2 , with doselimiting CNS toxicity at 1125 mg/m 2 ; 27 carboplatin had impressive antitumor activity at X1200 mg/m 2 and was safe in dosages up to 2000 mg/m 2 ; 29 and topotecan 10 mg/m 2 divided over 5 days became a commonly used salvage treatment because of impressive anticancer activity and modest toxicity, 11,13 though lower dosages were used in conventional combination chemotherapy regimens. [30] [31] [32] [33] [34] The 3 days of thiotepa preceded the 3 days of carboplatin, and the 5 days of topotecan were completed before the last dose of carboplatin. This schedule was based on concerns that nephrotoxic effects of carboplatin might alter pharmacokinetics of thiotepa, topotecan, and/or their cytotoxic metabolites, and thereby enhance toxicity. This scenario in fact appears to have occurred in a phase I dose-escalation study of topotecan used with 3 days of carboplatin followed by 3 days of thiotepa (same dosages of carboplatin and thiotepa as in our regimen): because of severe mucositis, 1.5 mg/m 2 /day Â 5 (total: 7.5 mg/m 2 ) was determined to be the maximally tolerated dosage of topotecan. 16 In our patients, the alternative drug scheduling As our experience attests, increasing numbers of children with high-risk NB are becoming long-term event-free survivors, with 3-year EFS rates (from diagnosis) in pilot studies as high as 50-60%. [36] [37] [38] Sophisticated use of conventional and myeloablative chemotherapy has improved remission rates and eradication of occult residual NB can be achieved with biological therapies such as 13-cisretinoic acid and monoclonal antibodies. Evidence of efficacy against CNS disease, however, is lacking for 13-cis-retinoic acid and monoclonal antibodies do not reach the CNS. In fact, all six of our patients with CNS relapse were treated post-SCT with one or both of these biological therapies; four also took oral etoposide, which is used for CNS malignancies. The inclusion of total body irradiation in myeloablative therapies may reduce the risk of NB relapse in the CNS, 36, 37 but that modality has been largely replaced by high-dose chemotherapy strategies. 38, 39 Of note, a recent report described CNS relapses in four of 15 patients treated with the widely used myeloablative regimen of carboplatin-etoposide-melphalan. 40 Busulfan might prove effective against NB in CNS. 39 Intrathecal treatments with chemotherapy 41, 42 and radiolabeled monoclonal antibodies are under investigation, 22, 23 but no risk factors have been conclusive for incorporating special prophylactic measures against occult NB in the CNS.
The prognosis of patients with relapse of NB in the CNS has been poor. 1, 40 We are piloting a multimodality program consisting of surgical resection, craniospinal irradiation, chemotherapy with irinotecan and temozolomide, intrathecal radiolabeled monoclonal antibodies, 3F8/GM-CSF immunotherapy, and 13-cis-retinoic acid. With that program, three of our most recent patients to relapse in the CNS have no evidence of NB 8 þ , 16 þ and 28 þ months after detection of their isolated brain relapses (patients 3, 4, and 6 in Table 1 ). These preliminary findings are encouraging and suggest that application of novel therapies may yield favorable results against this almost uniformly lethal type of relapse.
